IRBM has signed a service and development agreement with The University of Texas MD Anderson Cancer Center. The agreement will focus on the development of therapeutic monoclonal antibodies against a novel immune checkpoint target.   IRBM will work with MD Anderson’s Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform, part of the institution’s Therapeutics Discovery division focused on therapeutic antibody development. The parties will collaborate to identify and valid...